T. Schulz-Utermoehl

发表

Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia

Andrew G. Leach, T. Stankovic, L. Male, 2019, MedChemComm.

Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens.

R. Edwards, A. Boobis, T. Schulz-Utermoehl, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Application of HepG2/C3A liver spheroids as a model system for genotoxicity studies.

P. Lalor, N. Hodges, E. L. Shepherd, 2021, Toxicology letters.

Diclofenac metabolism in the mouse: Novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry

I. Wilson, S. Sarda, T. Schulz-utermoehl, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Acute liver effects, disposition and metabolic fate of [14C]-fenclozic acid following oral administration to normal and bile-cannulated male C57BL/6J mice

I. Wilson, S. Sarda, H. Jones, 2016, Archives of Toxicology.

In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid

I. Wilson, J. G. Kenna, S. Stahl, 2013, Archives of Toxicology.

Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers

I. Wilson, M. Hutchison, J. Swales, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers

I. Wilson, J. G. Kenna, Y. Morikawa, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly

S. Waddell, L. Alderwick, J. Fossey, 2020, bioRxiv.

Structure-function analysis of human CYP3A4 using a specific proinhibitory antipeptide antibody.

R. Bywater, K. Madsen, T. Schulz-utermoehl, 2000, Drug metabolism and disposition: the biological fate of chemicals.

OF HUMAN CYP 3 A 4 USING A SPECIFIC PROINHIBITORY ANTIPEPTIDE ANTIBODY

R. Bywater, K. Madsen, T. Schulz-utermoehl, 2000 .

Expression and localisation of CYP2D enzymes in rat basal ganglia

C. Marsden, R. Edwards, A. Boobis, 1999, Brain Research.

A semi-automated method for measuring the potential for protein covalent binding in drug discovery.

M. Beconi, R. White, T. Schulz-utermoehl, 2005, Journal of pharmacological and toxicological methods.

Characterisation and identification of the human N+-glucuronide metabolite of cediranib.

E. Lenz, T. Schulz-utermoehl, M. Harrison, 2010, Journal of pharmaceutical and biomedical analysis.

Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression.

G. Tucker, R. Edwards, A. Boobis, 1999, Pharmacogenetics.

The hepatic reductase null mouse as a model for exploring hepatic conjugation of xenobiotics: Application to the metabolism of diclofenac

I. Wilson, S. Sarda, E. Karlsson, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

In Vitro Hepatic Metabolism of Cediranib, a Potent Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor: Interspecies Comparison and Human Enzymology

S. Sarda, T. Schulz-utermoehl, N. Bushby, 2010, Drug Metabolism and Disposition.

In vitro models of xenobiotic metabolism in trout for use in environmental bioaccumulation studies

K. Chipman, S. Owen, S. Sarda, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

A quantitative high-throughput trapping assay as a measurement of potential for bioactivation.

A. Watt, Melanie Z Sakatis, Georgina Meneses-Lorente, 2006, Analytical biochemistry.

Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies.

R. Edwards, A. Boobis, T. Schulz, 2001, Biochimica et biophysica acta.

Differential Effect of Troglitazone on the Human Bile Acid Transporters, MRP2 and BSEP, in the PXB Hepatic Chimeric Mouse

I. Wilson, Y. Morikawa, J. Foster, 2012, Toxicologic pathology.